911 Shares in United Therapeutics Corporation $UTHR Bought by Waddell & Associates LLC

Waddell & Associates LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, HoldingsChannel reports. The fund acquired 911 shares of the biotechnology company’s stock, valued at approximately $444,000.

A number of other institutional investors have also made changes to their positions in the stock. Fox Run Management L.L.C. acquired a new stake in shares of United Therapeutics during the fourth quarter worth $1,280,000. Cerity Partners LLC grew its stake in shares of United Therapeutics by 134.3% during the fourth quarter. Cerity Partners LLC now owns 30,804 shares of the biotechnology company’s stock worth $15,009,000 after purchasing an additional 17,657 shares during the period. LPL Financial LLC grew its stake in shares of United Therapeutics by 3.1% during the fourth quarter. LPL Financial LLC now owns 10,186 shares of the biotechnology company’s stock worth $4,963,000 after purchasing an additional 302 shares during the period. Franklin Resources Inc. grew its stake in United Therapeutics by 189.0% in the fourth quarter. Franklin Resources Inc. now owns 181,120 shares of the biotechnology company’s stock valued at $88,251,000 after acquiring an additional 118,454 shares during the period. Finally, Erste Asset Management GmbH grew its stake in United Therapeutics by 13.8% in the fourth quarter. Erste Asset Management GmbH now owns 43,011 shares of the biotechnology company’s stock valued at $21,512,000 after acquiring an additional 5,223 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,712,246.04. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $547.49, for a total value of $5,201,155.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,180,462.37. This trade represents a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 634,043 shares of company stock worth $357,481,310 over the last three months. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $553.14 on Wednesday. The firm has a market cap of $23.48 billion, a price-to-earnings ratio of 20.42, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The stock’s 50-day moving average is $569.08 and its 200-day moving average is $520.18. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.63 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.